Dr. Philip Polgreen and his collaborators received a five-year, $3.7M R01 grant from the National Institute of Allergy and Infectious Diseasesto support the upcoming project titled, “Estimating the risk for and severity of respiratory infections attributable to CFTR heterozygosity.”